APA (7th ed.) Citation

Ascierto, P., Hassel, J. C., & Schadendorf, D. (2019). Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with Nivolumab therapy: Three-year follow-up of a randomized phase 3 trial. JAMA oncology, 5(2), . https://doi.org/10.1001/jamaoncol.2018.4514

Chicago Style (17th ed.) Citation

Ascierto, Paolo, Jessica C. Hassel, and Dirk Schadendorf. "Survival Outcomes in Patients with Previously Untreated BRAF Wild-type Advanced Melanoma Treated with Nivolumab Therapy: Three-year Follow-up of a Randomized Phase 3 Trial." JAMA Oncology 5, no. 2 (2019). https://doi.org/10.1001/jamaoncol.2018.4514.

MLA (9th ed.) Citation

Ascierto, Paolo, et al. "Survival Outcomes in Patients with Previously Untreated BRAF Wild-type Advanced Melanoma Treated with Nivolumab Therapy: Three-year Follow-up of a Randomized Phase 3 Trial." JAMA Oncology, vol. 5, no. 2, 2019, https://doi.org/10.1001/jamaoncol.2018.4514.